EUVIMEDEUVIMED entdecken
Crossref

L26/P-803 Impact of luteinizing hormone supplementation on euploid embryo yield: stratified analysis by age and AMH

M. Otsuki, Y. Ohara, M. Doshida, T. Takeuchi, H. Matsubayashi, T. Ishikawa

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Otsuki und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does luteinizing hormone(LH) supplementation during controlled ovarian stimulation improve euploid embryo yield in women undergoing preimplantation genetic testing for aneuploidy(PGT-A)? Summary answer LH supplementation was associated with a 36% increase in euploid embryo yield per 1,000 IU in women aged ≥43 years with AMH ≥1.2 ng/mL. What is known already The role of LH supplementation during controlled ovarian stimulation remains controversial. While some studies suggest potential benefits in specific patient populations, particularly those with advanced maternal age or diminished ovarian reserve, evidence regarding its impact on euploid embryo yield remains limited. Previous research has focused primarily on oocyte quantity rather than embryo quality assessed by PGT-A.Moreover, few studies have examined LH effects using stratification by both age and ovarian reserve markers such as AMH. Identifying subgroups that benefit most from LH supplementation may optimize individualized stimulation strategies in assisted reproduction. Study design, size, duration This retrospective cohort study analyzing 1,944 PGT-A cycles performed at two fertility centers between August 2020 and December 2023. Patients were stratified by age (≤37, 38-42, ≥43 years) and ovarian reserve according to AMH levels (<1.2 or ≥ 1.2 ng/mL). Multivariable Poisson regression with robust standard errors was used to assess the association between total LH dose and euploid embryo yield, adjusting for potential confounders. Participants/materials, setting, methods Women undergoing controlled ovarian stimulation with subsequent embryo biopsy for PGT-A were included. Total LH dose, expressed per 1,000 IU increment, was the primary exposure. The number of euploid or mosaic embryos served as the outcome. Multivariable Poisson regression models adjusted for age, AMH, BMI, retrieved oocytes, blastocyst number, and total FSH dose. Subgroup analyses assessed effect modification by age and AMH-defined ovarian reserve. Main results and the role of chance Among 1,944 cycles analyzed, mean age was 41.0±3.2 years and mean AMH was 2.2±2.2 ng/mL. Subgroup analysis revealed significant heterogeneity in the association between LH supplementation and euploid embryo yield across age and ovarian reserve strata. In women aged 43 years or older with AMH ≥1.2 ng/mL (n = 398), each 1,000 IU increase in total LH dose was associated with a 36% increase in euploid embryo yield (IRR 1.364, 95% CI 1.035-1.797, p = 0.027), after adjusting for age, AMH, BMI, oocyte yield, blastocyst count, and total FSH dose. This association remained statistically significant and clinically meaningful. No significant associations were observed in other subgroups: age ≤37 with AMH <1.2 (IRR 0.835, p = 0.261), age ≤37 with AMH ≥1.2 (IRR 0.974, p = 0.774), age 38-42 with AMH <1.2 (IRR 0.926, p = 0.343), age 38-42 with AMH ≥1.2 (IRR 1.005, p = 0.939), or age ≥43 with AMH <1.2 (IRR 0.691, p = 0.094). Limitations, reasons for caution Retrospective design limits causal inference. LH supplementation was not randomly assigned. Unmeasured confounding factors may exist. Results may not generalize to other populations or protocols. External validation in prospective randomized trials is needed before clinical implementation. Wider implications of the findings These findings suggest that LH supplementation may benefit a specific patient subgroup: women of advanced maternal age with preserved ovarian reserve. Personalized ovarian stimulation protocols based on age and ovarian reserve status could optimize euploid embryo yield and improve outcomes in assisted reproduction. Trial registration number No

Zitieren

APA

Otsuki, M., Ohara, Y., Doshida, M., Takeuchi, T., Matsubayashi, H., & Ishikawa, T. (2026). L26/P-803 Impact of luteinizing hormone supplementation on euploid embryo yield: stratified analysis by age and AMH. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1130

Vancouver

Otsuki M, Ohara Y, Doshida M, Takeuchi T, Matsubayashi H, Ishikawa T. L26/P-803 Impact of luteinizing hormone supplementation on euploid embryo yield: stratified analysis by age and AMH. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1130

BibTeX
@article{Otsuki2026,
  author = {Otsuki, M. and Ohara, Y. and Doshida, M. and Takeuchi, T. and Matsubayashi, H. and Ishikawa, T.},
  title = {L26/P-803 Impact of luteinizing hormone supplementation on euploid embryo yield: stratified analysis by age and AMH},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1130}
}
Kostenlos starten →